Recombinant Human Lactate Dehydrogenase A/LDHA Protein, CF

• Reactivity: Hu
• Applications: Enzyme Activity
• Format: Carrier-Free

Recombinant Human Lactate Dehydrogenase A/LDHA Protein, CF Summary

• Details of Functionality: Measured by its ability to reduce pyruvate to lactate. The specific activity is >95,000 pmol/min/μg, as measured under the described conditions.
• Source: E. coli-derived human Lactate Dehydrogenase A/LDHA protein
  Ala2-Phe332, with N-terminal Met and 6-His tag
• Accession #: P00338
• N-terminal Sequence: Met
• Protein/Peptide Type: Recombinant Enzymes
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Enzyme Activity
• Theoretical MW: 38 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 36 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in Tris, NaCl and Glycerol.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Assay Procedure:
  • Assay Buffer: 25 mM Tris, 100 mM NaCl, pH 7.5
  • Recombinant Human Lactate Dehydrogenase A/LDHA (rhLDHA) (Catalog # 9158-HA)
  • beta -Nicotinamide adenine dinucleotide, reduced disodium salt hydrate ( beta -NADH) (Sigma, Catalog # N8129), 20 mM stock in 0.1 M Sodium Borate, pH 9.0
  • 100 mM Sodium Pyruvate (Gibco, Catalog # 11360)
  • 96-well Clear Plate (Catalog # DY990)
  • Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent
  1. Dilute rhLDHA to 0.4 ng/µL in Assay Buffer.
  2. Prepare a substrate mixture containing 1.6 mM beta -NADH and 4 mM sodium pyruvate in Assay Buffer.
  3. In a plate load 50 µL of 0.4 ng/µL rhLDHA, and start the reaction by adding 50 µL of substrate mixture. Include a Substrate Blank containing 50 µL Assay Buffer and 50 µL of substrate mixture.
  4. Read plate at 340 nm (absorbance) in kinetic mode for 5 minutes.
  5. Calculate specific activity:

  Specific Activity (pmol/min/µg) = (Adjusted Vmax* (OD/min) x well volume (L) x 10^12 pmol/mol x (-1)) / (ext. coeff** (M^-1cm^-1) x path corr.*** (cm) x amount of enzyme (µg))

  
  *Adjusted for Substrate Blank.
  **Using the extinction coefficient 6220 M^-1cm^-1_.
  ***Using the path correction 0.320 cm.
  Note: the output of many spectrophotometers is in mOD.

  Per Well:
  • rhLDHA: 0.020 µg
  • beta -NADH: 0.8 mM
  • Sodium pyruvate: 2 mM

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Lactate Dehydrogenase A/LDHA Protein, CF

• Cell proliferation-inducing gene 19 protein
• EC 1.1.1
• EC 1.1.1.27
• GSD11
• Lactate Dehydrogenase A
• lactate dehydrogenase M
• LDH muscle subunit
• LDH1
• LDHA
• LDH-A
• LDHM
• LDH-M
• L-lactate dehydrogenase A chain
• proliferation-inducing gene 19
• Renal carcinoma antigen NY-REN-59

Background

A hallmark of most cancer cells is an altered metabolism involving a shift to aerobic glycolysis with lactate production coupled with a higher uptake of glucose as the main source of energy. Lactate dehydrogenase (LDH) is key to this shift by catalyzing the formation of lactate by reducing pyruvate with NADH, which also generates NAD(+) that is essential for the continuity of glycolysis (1). LDHA is a key enzyme that controls the production of lactate in the glycolysis pathway. It is therefore an important control point in the system of cellular energy release. It's up regulation is common in many malignant tumors. Inhibiting LDH activity has an anti-proliferative effect on cancer cells (2). It may reverse the resistance of tumor cells to conventional chemo- and radiotherapy. Recent research has renewed interest in LDH as an anticancer drug target (3).The protein is found predominantly in muscle tissue. Mutations in LDHA have been linked to exertional myoglobinuria (4).

1. Faloppi L. et al. (2016) Sci Rep. doi: 10.1038/srep24136.
2. Ghosh, M. et al. (2016) Chem. Commun. 52:2401.
3. Augoff, K. et al. (2015) Cancer Lett. 358:1.
4. Maekawa M. et al. (1990). Biochem. Biophys. Res. Commun. 168:677.

Bioinformatics

• Uniprot:
  • P00338(Human)